Moderna Raises Annual Revenue Forecast on Vaccine Demand
Moderna lifted its full-year revenue forecast after strong international vaccine demand helped the biotech swing to a third-quarter profit. The company reported $1.3 billion in revenue, beating expectations.
Xurve View
Insights:
Xurve View
MODERNA INC raised its full-year revenue forecast to 15% growth after strong international vaccine demand helped the biotech swing to a $162 million profit. The upbeat performance follows promising clinical data for its personalized cancer vaccine candidate. Investors are now turning their attention to commercial readiness and cost discipline ahead of its 2028 targets.
